[go: up one dir, main page]

MX2014015551A - Compuestos iduronidasa apuntados. - Google Patents

Compuestos iduronidasa apuntados.

Info

Publication number
MX2014015551A
MX2014015551A MX2014015551A MX2014015551A MX2014015551A MX 2014015551 A MX2014015551 A MX 2014015551A MX 2014015551 A MX2014015551 A MX 2014015551A MX 2014015551 A MX2014015551 A MX 2014015551A MX 2014015551 A MX2014015551 A MX 2014015551A
Authority
MX
Mexico
Prior art keywords
compounds
iduronidase
targeted
idua
compound
Prior art date
Application number
MX2014015551A
Other languages
English (en)
Inventor
Boivin Dominique
Castaigne Jean-Paul
Demeule Michel
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of MX2014015551A publication Critical patent/MX2014015551A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con un compuesto que incluye (a) a-L-iduronidasa (IDUA), un fragmento o análogo de la misma, y (b) una fracción que apunta, por ejemplo donde el compuesto es una proteína de fusión que incluye IDUA y Angiopep-2. En ciertas formas de realización estos compuestos, debido a la presencia de la fracción que apunta, pueden cruzar la barrera hematoencefálica o acumularse en el lisosoma de manera más efectiva que la enzima sola. La invención también se refiere a métodos para tratar mucopolisacaridosis tipo I (MPS-I) usando tales compuestos.
MX2014015551A 2012-06-15 2013-06-14 Compuestos iduronidasa apuntados. MX2014015551A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660564P 2012-06-15 2012-06-15
US201261732189P 2012-11-30 2012-11-30
PCT/CA2013/050453 WO2013185235A1 (en) 2012-06-15 2013-06-14 Targeted iduronidase compounds

Publications (1)

Publication Number Publication Date
MX2014015551A true MX2014015551A (es) 2016-09-19

Family

ID=49757375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015551A MX2014015551A (es) 2012-06-15 2013-06-14 Compuestos iduronidasa apuntados.

Country Status (9)

Country Link
US (1) US20150147310A1 (es)
EP (1) EP2861729A4 (es)
JP (1) JP2015521463A (es)
CN (1) CN104662151A (es)
AU (1) AU2013273894A1 (es)
BR (1) BR112014031273A2 (es)
CA (1) CA2876525A1 (es)
MX (1) MX2014015551A (es)
WO (1) WO2013185235A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2260874A1 (en) 2003-01-06 2010-12-15 Angiochem Inc. Aprotinin analogs as carriers across the blood-brain barrier
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CA2747220A1 (en) 2008-12-17 2010-06-24 Richard Beliveau Membrane type-1 matrix metalloprotein inhibitors and uses thereof
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
AU2013302270A1 (en) 2012-08-14 2015-03-26 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
WO2016090495A1 (en) * 2014-12-11 2016-06-16 Angiochem Inc. TARGETED α-L-IDURONIDASE CONJUGATES AND USES THEREOF
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487815A1 (en) * 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
WO2004108071A2 (en) * 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
JP5624256B2 (ja) * 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
PL1877099T3 (pl) * 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
EP2235175A4 (en) * 2007-12-20 2012-04-25 Angiochem Inc POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF
RU2011125366A (ru) * 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
WO2010063122A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
HK1204002A1 (en) * 2011-12-01 2015-11-06 Angiochem Inc. Targeted lysosomal enzyme compounds
BR112014013250A2 (pt) * 2011-12-01 2019-09-24 Angiochem Inc compostos com enzima alvo e usos dos mesmos

Also Published As

Publication number Publication date
BR112014031273A2 (pt) 2017-07-25
AU2013273894A1 (en) 2015-02-05
US20150147310A1 (en) 2015-05-28
CA2876525A1 (en) 2013-12-19
EP2861729A4 (en) 2016-04-13
EP2861729A1 (en) 2015-04-22
WO2013185235A1 (en) 2013-12-19
JP2015521463A (ja) 2015-07-30
CN104662151A (zh) 2015-05-27

Similar Documents

Publication Publication Date Title
MX2014015551A (es) Compuestos iduronidasa apuntados.
MX2014006594A (es) Compuestos de enzimas lisosomales apuntados.
WO2013078562A3 (en) Targeted iduronate-2-sulfatase compounds
PH12019550261A1 (en) Compositions and methods for internalizing enzymes
CY1122555T1 (el) Στοχευμενες θεραπευτικες πρωτεϊνες συντηξης λυσωσομικων ενζυμων και χρησεις αυτων
PH12020550510A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
PH12018501074A1 (en) Compositions and methods for internalizing enzymes
MX337248B (es) Variantes de plasminogeno y plasmina.
EA201501068A1 (ru) Стабильные составы на основе фермента, разрушающего гиалуронан
MX347808B (es) Variantes de plasminogeno y plasmina.
UA114090C2 (uk) Сполуки, що інгібують металоферменти
MX2013001580A (es) Composiciones que comprenden un polipeptido que tiene actividad de incremento celulolitico y un licor, y usos de las mismas.
MX348003B (es) Metodos y medios para modificar un genoma vegetal.
MX2012000475A (es) Variantes de plasminogeno y plasmina.
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
BR112014013963A8 (pt) compostos inibidores de metaloenzimas
EA201490052A1 (ru) Соединения, ингибирующие металлоферменты
EA201490036A1 (ru) Соединения, ингибирующие металлоферменты
MX2017001898A (es) Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
HK1223632A1 (zh) 靶向的酶化合物及其用途
CY1119064T1 (el) Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων
EA201390876A1 (ru) Соединения, ингибирующие металлоферменты